What is the equivalent dose of ropinirole (Requip) extended-release (ER) for a patient taking ropinirole 0.5 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Equivalent Dosing of Ropinirole Extended-Release for Patients on Immediate-Release 0.5 mg

The equivalent dose when converting from ropinirole immediate-release 0.5 mg to extended-release formulation is 2 mg of ropinirole extended-release.

Conversion Ratios for Ropinirole Formulations

  • A 1:4 conversion ratio (1 mg immediate-release to 4 mg extended-release) is recommended when switching from immediate-release to extended-release ropinirole, resulting in fewer discontinuations, fewer dose adjustments, and higher patient preference 1
  • For a patient taking 0.5 mg of immediate-release ropinirole, the equivalent extended-release dose would be 2 mg (0.5 mg × 4 = 2 mg) 1
  • Patients can be converted overnight between ropinirole formulations without loss of efficacy and with good tolerability 2

Benefits of Extended-Release Formulation

  • Extended-release ropinirole allows for once-daily dosing compared to three-times-daily dosing with immediate-release formulation 3
  • The extended-release formulation provides more consistent dopaminergic activity with steadier plasma levels throughout the day 2
  • Once-daily dosing may improve medication adherence and simplify the dosing regimen 2
  • Extended-release formulation allows for faster titration with good tolerability 3

Clinical Considerations

  • The American Academy of Sleep Medicine suggests against the standard use of ropinirole for restless legs syndrome due to concerns about long-term adverse effects, particularly augmentation 4, 5
  • If used for RLS, ropinirole should be reserved for patients who prioritize short-term symptom reduction over concerns about long-term adverse effects 4, 5
  • Common side effects of ropinirole include gastrointestinal effects (nausea, vomiting), somnolence, dizziness, and orthostatic hypotension 5
  • Monitor for compulsive behaviors, which are a potential serious side effect of ropinirole, including unusual urges such as gambling, increased sexual urges, uncontrollable shopping, and compulsive eating 5
  • Older patients are at particular risk for orthostasis, drug interactions, and hallucinations when taking ropinirole 5

Important Dosing Considerations

  • The extended-release formulation should be swallowed whole and not crushed or chewed, as this would disrupt the controlled-release mechanism 2
  • Extended-release ropinirole should be taken once daily, preferably at the same time each day 3
  • In clinical studies for RLS, the mean effective dosage was typically lower than the maximum (around 0.78-0.89 mg of immediate-release), suggesting that the 2 mg extended-release dose may be sufficient for many patients 6
  • If dose adjustments are needed after conversion, they should be made gradually based on efficacy and tolerability 2

Potential Pitfalls and Caveats

  • Patients on higher doses of immediate-release ropinirole (>4 mg/day) and those with longer disease duration may have more difficulty with conversion to extended-release formulation 1
  • Be aware of the augmentation phenomenon, characterized by worsening and earlier onset of symptoms in patients initially controlled on ropinirole 5
  • Extended-release ropinirole may achieve higher daily doses compared to immediate-release formulation, which may require adjustment of concomitant medications like levodopa in Parkinson's disease patients 7

References

Research

An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society, 2009

Research

A review of ropinirole prolonged release in Parkinson's disease.

Clinical interventions in aging, 2009

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Ropinirole Side Effects and Clinical Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Ropinirole Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.